Live Breaking News & Updates on Sodium Glucose Cotransporter 2 Inhibitors

Stay updated with breaking news from Sodium glucose cotransporter 2 inhibitors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SGLT2-inhibitors: No Benefit in Hospitalized COVID-19

However, an important take-home message from this new meta-analysis is that these widely used medications appeared to be safe even in acutely ill hospitalized patients, the researchers say. ....

United States , Noord Holland , Mikhail Kosiborod , Muthiah Vaduganathan , Medscape Coronavirus Resource Center , World Health Organization , European Society Of Cardiology , Saint Luke Mid America Heart Institute , Coronavirus Resource , Saint Luke , Mid America Heart Institute , Kansas City , European Society , Rapid Evidence Appraisal , Working Group , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronavirus Oc43 , Cov Oc43 , Uman Coronavirus 229e , Cov 229e , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors , Odium Glucose Co Transporter 2 Inhibitors ,

SGLT2i Safety in Acute Heart Failure Confirmed by New Data

Results of the DICTATE-AHF randomized trial that tested starting dapagliflozin for patients hospitalized with acute heart failure confirmed the safety and benefit of this guideline-directed strategy. ....

United States , Noord Holland , Zachary Cox , Stephend Wiviott , Harvard Medical School , Boehringer Ingelheim , European Society Of Cardiology , Lipscomb University College Of Pharmacy , European Society , Lipscomb University College , Heart Failure , Acute Heart Failure , Acute Hf , Cardiovascular Imaging , Ardiac Imaging , V Imaging , Clinical Guidelines , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors , Odium Glucose Co Transporter 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii ,

Diabetes Drug Class Appears to Reduce Recurrent Gout Flares

Previously associated with a lower incidence of gout, sodium-glucose cotransporter-2 (SGLT2) inhibitors for the first time also appear to reduce gout flare recurrence and excess mortality. ....

United States , United Kingdom , Hunan Province , Los Angeles , Johnd Fitzgerald , Jie Wei , University Of California , Natural Science Foundation Of Hunan Province , National Key Research , Development Plan , Central South University , Program Of National Clinical Research Center , Technology Department Of Hunan Province , American College Of Rheumatology , Health Management Center , National Natural Science Foundation Of China , Xiangya Hospital , Medscape Medical News , Gout Recurrence , Lower Mortality , American College , National Natural Science Foundation , Project Program , National Clinical Research Center , Geriatric Disorders , Natural Science Foundation ,

SGLT2 Inhibitors Curb AF Post-Ablation Recurrences in T2D

Retrospective, observational data from more than 13,000 US patients with type 2 diabetes and atrial fibrillation suggest that SGLT2 inhibitor treatment may cut AF recurrences post-ablation. ....

United States , James Januzzi Jr , Division Of Cardiovascular Medicine , Trinetx Analytics Network , Beth Israel Lahey Health , Cardiovascular Medicine , Lahey Hospital , Medical Center , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Atrial Fibrillation , F Atrial Fibrillation , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors , Odium Glucose Co Transporter 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors , Healthcare Technology , Ealth Care Technology , Electronic Medical Record Emr , Electronic Medical Record , Omputerized Medical Reco ,

SGLT2 inhibitors reduce recurrent flares and hospitalizations in patients with gout

1. In this population cohort study, patients with gout who used sodium-glucose cotransporter-2 inhibitors (SGLT2is) experienced fewer recurrent flares than those using dipeptidyl peptidase 4 inhibitors (DPP-4is). 2. Those who used SGLT2 inhibitors also presented to the emergency department (ED) less frequently for gout-related visits than those using DPP-4is. Evidence Rating Level: 1 (Excellent) Study ....

United Kingdom , International Statistical Classification Of Diseases , Health Problems , Minute Medicine Inc , Rating Level , Gout With Sodium , Patients With Type , British Columbia , International Statistical Classification , Related Health Problems , Confidence Interval , Chronic Disease , Dipeptidyl Peptidase 4 Inhibitors , Inflammatory Arthritis , Sglt 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors ,